Clinical Trials
24
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT
- Conditions
- Leber Congenital Amaurosis (LCA)Retinitis Pigmentosa (RP)
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- QLT Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT02575430
- Locations
- 🇺🇸
Wilmer Eye Institute - Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Casey Eye Institute - Marquam Hill, Portland, Oregon, United States
🇨🇦The Hospital for Sick Children, Ophthalmology and Vision Sciences, Toronto, Ontario, Canada
Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- QLT Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT01999764
- Locations
- 🇺🇸
Sall Research Medical Center, Artesia, California, United States
🇺🇸California Retina Consultants, Santa Barbara, California, United States
🇺🇸Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- QLT Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01543906
- Locations
- 🇨🇦
Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada
🇮🇪Royal Victoria Eye and Ear Hospital, Dublin, Ireland
Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)
- Conditions
- RP (Retinitis Pigmentosa)LCA (Leber Congenital Amaurosis)
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- QLT Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT01521793
- Locations
- 🇺🇸
The Chicago Lighthouse (University of Illinois at Chicago, Pangere Center for Inherited Retinal Disease), Chicago, Illinois, United States
🇺🇸Wilmer Eye Institute (Johns Hopkins University), Baltimore, Maryland, United States
🇨🇦Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada
Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations
- Conditions
- LCA (Leber Congenital Amaurosis)RP (Retinitis Pigmentosa)
- First Posted Date
- 2009-11-16
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- QLT Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01014052
- Locations
- 🇺🇸
The Chicago Lighthouse for People Who Are Blind or Visually Impaired (The Pangere Center For Inherited Retinal Diseases), Chicago, Illinois, United States
🇺🇸Wilmer Eye Institute (Johns Hopkins University), Baltimore, Maryland, United States
🇺🇸Scheie Eye Institute, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- 3
- 4
- Next